Claims for Patent: 5,755,237

Summary for Patent: 5,755,237

Title:	Therapeutic use of acetazolamide for the treatment of brain edema
Abstract:	A method for treating victims of cerebral edema is presented that includes the intravenous injection of acetazolamide (A.K.A., DIAMOX.RTM.), which is a readily-available and often-prescribed diuretic. Such edema, or brain swelling may be caused as a result of ischemic strokes especially, but also swelling due to tumors, surgeries, or cerebral trauma. It is preferred to combine the acetazolamide therapy with hyperventilation of the lungs, even including the use of supplemental oxygen, thereby to reduce the concentration of carbon dioxide in the blood and hence in the brain.
Inventor(s):	Rodriguez; Victorio C. (Parma, OH)
Assignee:
Application Number:	08/490,110
Patent Claims:	1. A therapeutic medical method of treatment of a human patient suffering from the effects of brain edema, said method comprising administering acetazolamide to said human patient. 2. The method of claim 1 wherein said administering acetazolamide is by intravenously injecting of a mixture comprising acetazolamide and sterile water. 3. The method of claim 2 wherein said mixture comprises approximately 500 milligrams of acetazolamide and approximately 5 milliliters of sterile water. 4. The method of claim 2 wherein said mixture is a solution, said acetazolamide is a solute, and said water is a solvent. 5. The method of claim 2 wherein said mixture comprises approximately 250 to 500 milligrams of acetazolamide and approximately 2.5 to 5 milliliters of sterile water. 6. The method of claim 5 wherein said mixture is a solution, said acetazolamide is a solute, and said water is a solvent. 7. The method of claim 1 wherein said administering acetazolamide is accomplished by medicating said patient by ingestion. 8. The method of claim 1 wherein a first dose of said acetazolamide is administered by intravenously injecting a mixture comprising acetazolamide and sterile water and administering a subsequent dose of acetazolamide by ingestion. 9. The method of claim 1, 2, 7, or 8 wherein said administering acetazolamide is combined with hyperventilating the patient. 10. The method of claim 9 wherein said hyperventilating comprises increasing the concentration of oxygen in respiratory air. 11. A therapeutic medical method of treatment of a human patient suffering from the effects of brain edema specifically caused by ischemic stroke, said method comprising administering acetazolamide to said human patient. 12. The method of claim 11 wherein said administering acetazolamide is by intravenously injecting a mixture comprising acetazolamide and sterile water. 13. The method of claim 12 wherein said mixture comprises approximately 500 milligrams of acetazolamide and approximately 5 milliliters of sterile water. 14. The method of claim 12 wherein said mixture is a solution, said acetazolamide is a solute, and said water is a solvent. 15. The method of claim 12 wherein said mixture comprises approximately 250 to 500 milligrams of acetazolamide and approximately 2.5 to 5 milliliters of sterile water. 16. The method of claim 15 wherein said mixture is a solution, said acetazolamide is a solute, and said water is a solvent. 17. The method of claim 11 wherein said administering acetazolamide is accomplished by medicating said patient by ingestion. 18. The method of claim 11 wherein a first dose of said acetazolamide is administered by intravenously injecting a mixture comprising acetazolamide and sterile water and administering a subsequent dose of acetazolamide by ingestion. 19. The method of claim 11, 12, 17, or 18 wherein said administering acetazolamide is combined with hyperventilating the patient. 20. The method of claim 19 wherein said hyperventilating comprises increasing the concentration of oxygen in respiratory air.

Details for Patent 5,755,237

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23